project id: TCGA-BLCA; case submitter id: TCGA-DK-A3IQ; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.79; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.0; rna integrity number: 7.1; age at index: 74; days to birth: -27194; days to death: 539; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Dead; year of birth: 1937; age at diagnosis: 27194; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage III; ajcc pathologic t: T3; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 319.0; icd 10 code: C67.4; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Posterior wall of bladder; synchronous malignancy: Not Reported; tissue or organ of origin: Posterior wall of bladder; tumor grade: Not Reported; year of diagnosis: 2011; alcohol history: Not Reported; cigarettes per day: 2.191780821917808; pack years smoked: 40.0; is ffpe: false; composition: Not Reported; days to collection: 230; days to sample procurement: 0; initial weight: 280.0; portion submitter id: TCGA-DK-A3IQ-01A-31; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 20.0; percent stromal cells: 5.0; percent tumor cells: 75.0; percent tumor nuclei: 75.0;